Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -753.96% is 58% above its 5-year average of -1800.63%, near the high end of its 5-year range (-4002.67%–-753.96%).
24.77% above its 12-month average of -1002.21%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2007 (2007-09-30): -1010.02%.
EBITDA MARGIN
-753.96%
EBITDA MARGIN AVG TTM
-1002.21%
EBITDA MARGIN AVG 3Y
-1472.86%
EBITDA MARGIN AVG 5Y
-1800.63%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.77%
CURRENT VS 3Y AVG
+48.81%
CURRENT VS 5Y AVG
+58.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Oncolytics Biotech Inc.
Market Cap
$60.21M
EBITDA Margin
-753.96%
TTM Avg
-1002.21%
3Y Avg
-1472.86%
5Y Avg
-1800.63%
Market Cap
$60.03M
EBITDA Margin
-92.40%
TTM Avg
-510.72%
3Y Avg
-510.72%
5Y Avg
-510.72%
Market Cap
$59.46M
EBITDA Margin
-270.28%
TTM Avg
-442.93%
3Y Avg
-1031.00%
5Y Avg
-861.19%
Market Cap
$59.41M
EBITDA Margin
-89640.62%
TTM Avg
-44862.17%
3Y Avg
-44862.17%
5Y Avg
-44862.17%
Market Cap
$62.69M
EBITDA Margin
-99843.01%
TTM Avg
-70984.01%
3Y Avg
-70984.01%
5Y Avg
-70984.01%
Market Cap
$61.44M
EBITDA Margin
-16170.91%
TTM Avg
-8243.87%
3Y Avg
-8243.87%
5Y Avg
-8243.87%
Market Cap
$58.16M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$57.69M
EBITDA Margin
-3226.05%
TTM Avg
-3226.05%
3Y Avg
-3226.05%
5Y Avg
-3226.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $60.21M | -753.96% | -1002.21% | -1472.86% | -1800.63% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.03M | -92.40% | -510.72% | -510.72% | -510.72% |
| Adicet Bio, Inc. (ACET)vs › | $59.46M | -270.28% | -442.93% | -1031.00% | -861.19% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.41M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
| Fractyl Health, Inc. (GUTS)vs › | $62.69M | -99843.01% | -70984.01% | -70984.01% | -70984.01% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.44M | -16170.91% | -8243.87% | -8243.87% | -8243.87% |
| Boundless Bio, Inc. (BOLD)vs › | $58.66M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.16M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $57.69M | -3226.05% | -3226.05% | -3226.05% | -3226.05% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | -11538.23% | -6406.80% | -3544.47% | -2835.62% |
Gross Margin
0.0%
EBITDA Margin
-754.0%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2007-09-30 | -1010.02% |
| 2006-09-30 | -994.40% |
| 2006-06-30 | -822.68% |
| 2006-03-31 | -950.94% |
| 2005-12-31 | -4002.67% |
| 2005-09-30 | -1304.64% |
| 2005-06-30 | -1583.92% |
| 2005-03-31 | -880.94% |
| 2004-12-31 | -1849.67% |
| 2004-09-30 | -1328.68% |
| 2004-06-30 | -1579.59% |
| 2004-03-31 | -2163.73% |
| 2003-12-31 | -1383.11% |
| 2003-09-30 | -1619.53% |
| 2003-06-30 | -3845.73% |
| 2003-03-31 | -2220.27% |
| 2002-12-31 | -3508.11% |
| 2002-09-30 | -3564.66% |
